M&A - Alto Neuroscience, Inc.

Form Type: 8-K

Filing Date: 2025-06-03

Corporate Action: Acquisition

Type: New

Accession Number: 000199948025000048

Filing Summary: On May 31, 2025, Alto Neuroscience, Inc. entered into an Asset Purchase Agreement with Chase Therapeutics Corporation to acquire rights to the novel compounds CTC-501 and CTC-413, including related intellectual property and other assets. The initial payment was $1,750,000, with an additional potential of up to $71,500,000 in milestone payments tied to clinical and regulatory achievements. Some of these payments can be made in the form of restricted shares totaling a maximum of 5,387,353 shares. The Company must develop and commercialize products containing these compounds and has assumed certain liabilities post-transaction. A press release on June 3, 2025, announced this acquisition and emphasized its significance for treatment resistant depression, aligning with the company's current cash runway.